Thank you for joining us in 2022!

Breast Cancer Immunotherapy

November 12, 2022, 2:25 pm -
3:00 pm
Rapid research developments and new treatment combinations

Session Description

Breast cancer is one of the most diagnosed cancers among women, with an estimated 2.1 million new cases of breast cancer globally each year. Immunotherapy for breast cancer is developing rapidly following the first FDA-approved checkpoint inhibitor for triple-negative breast cancer in March 2019. New treatment regimens combining immunotherapy with chemotherapy, radiation, or surgery are showing promise in clinical trials. Dr. Elizabeth Mittendorf of Dana-Farber/Harvard Cancer Center will answer your questions and discuss current immunotherapy research for breast cancer.


Elizabeth Ann Mittendorf, MD, PhD

Dana-Farber/Harvard Cancer Center

Dr. Elizabeth Mittendorf is the Robert and Karen Hale Distinguished Chair in Surgical Oncology and Vice Chair for Research in the Department of Surgery at the Brigham and Women’s Hospital. She is also Co-Leader of the Breast Program for the Dana-Farber/Harvard Cancer Center and the Director of the Breast Immuno-Oncology Program at the Dana-Farber Cancer Institute. She serves as the co-leader of the National Cancer Institute Breast Immuno-Oncology Task Force and the leader of the Immunotherapy Working Group within the Translational Breast Cancer Research Consortium. Dr. Mittendorf received her medical degree from Case Western Reserve University where she also completed a General Surgery residency. She served in the US military before completing a Surgical Oncology fellowship at the MD Anderson Cancer Center. Dr. Mittendorf also holds a PhD in Immunology from the University of Texas and a Masters in Healthcare Management from Harvard. Dr. Mittendorf focuses her clinical and laboratory efforts on the study of breast cancer with a specific interest in immunotherapy. She has been the principal investigator on several trials investigating CD8+ T cell eliciting vaccines based on preclinical data generated in her laboratory. More recently she led the phase III IMpassion031 study that showed an increase in the pCR rate when the immunotherapeutic agent Atezolizumab was given in the preoperative setting for triple negative breast cancer patients. Her current laboratory work is investigating the impact of standard and experimental therapies on immunologic aspects of the tumor microenvironment as well as the effect of race and aging on the immune response to cancer. Dr. Mittendorf has also published extensively on subjects related to breast cancer including incorporation of biologic factors into staging, selection of patients for preoperative systemic therapy, and surgical management following receipt of preoperative systemic therapy.